Delisting risk
FLNA · NASDAQ · Biotechnology

Filana Therapeutics

Developing simufilam, an oral small molecule, for TSC-related epilepsy.

$0.9280
After-hours close−0.00 (−0.03%)
At close$0.9283(+0.57%)
DateEstimateReportedSurprise
Oct 2026−$0.25
Jul 2026−$0.23−$0.18+20.0%
May 2026−$0.23−$0.21+8.7%
Mar 2026−$0.30−$0.26+13.3%
Report dateEPS estEPSSurpriseRevenue estRevenueSurprise
Oct 29, 2026−$0.25
Jul 29, 2026−$0.23−$0.18+20.0%
May 7, 2026−$0.23−$0.21+8.7%
Mar 12, 2026−$0.30−$0.26+13.3%